Abstract
Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have